ArticleOncotarget2017
Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Risk of intracranial meningioma in patients with acromegaly: a systematic review.Frontiers in endocrinology · 2024Pooled it
- Somatostatin analogues in treatment-refractory meningioma: a systematic review with meta-analysis of individual patient data.Neurosurgical review · 2022Pooled it
- Pasireotide Exerts Anti-Inflammatory Effects in the Endothelium.Journal of biochemical and molecular toxicology · 2025Article
- Assessing the diagnostic, prognostic, and therapeutic potential of the somatostatin/cortistatin system in glioblastoma.Cellular and molecular life sciences : CMLS · 2025Article
- Expression of somatostatin receptors in canine and feline meningioma.Veterinary medicine and science · 2024Article
- Meningiomas and Somatostatin Analogs: A Systematic Scoping Review on Current Insights and Future Perspectives.International journal of molecular sciences · 2023Article
- Co-Targeting MAP Kinase and Pi3K-Akt-mTOR Pathways in Meningioma: Preclinical Study of Alpelisib and Trametinib.Cancers · 2022Article
- Advances in Molecular Biological and Translational Studies in World Health Organization Grades 2 and 3 Meningiomas: A Literature Review.Neurologia medico-chirurgica · 2022Review
- Differences in the expression of SSTR1-5 in meningiomas and its therapeutic potential.Neurosurgical review · 2022Article
- Clinical Significance of Somatostatin Receptor (SSTR) 2 in Meningioma.Frontiers in oncology · 2020Review
- Toward fully exploiting the therapeutic potential of marketed pharmaceuticals: the use of octreotide and chloroquine in oncology.OncoTargets and therapy · 2019Review
- An overview of meningiomas.Future oncology (London, England) · 2018Review
- Cytotoxicity on low-grade canine meningioma with the use of somatostatin analog (octreotide): An in vitro study.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pasireotide is a somatostatin analog (SSA) that targets somatostatin receptor subtype 1 (SST1), SST2, SST3, and SST5 with a high affinity. Pasireotide has a better antisecretory effect in acromegaly, Cushing's disease, and neuroendocrine tumors than octreotide. In this study, we compared the effects of pasireotide to those of octreotide
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.